Декапептил 0,1 мг/мл раствор для инъекций

국가: 키르기스스탄

언어: 러시아어

출처: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

유효 성분:

Трипторелин

제공처:

Ферринг ГмбХ

ATC 코드:

L02AE04

INN (International Name):

Triptorelin

복용량:

0,1 мг/мл

약제 형태:

раствор для инъекций

패키지 단위:

№7

처방전 유형:

по рецепту

Manufactured by:

Ферринг ГмбХ (Германия)

치료 영역:

Противоопухолевое средство

제품 요약:

ПЖВЛС: нет

승인 날짜:

2016-10-26

제품 특성 요약

I,IHCTPYKUIIflTIOMEAIIUIIHCKOMYTIPI'IMEHEHIIIOJIEKAPCTBEHHOTO
CPEACTBA
AEKATIEIITI,IJI
Topronoe
Ha3BaHIre,{eraneurun
Mex4yuapoAuoe
HerIareHToBaHHoe
lra3Balr[e
rpI4IITopenI'IH
Cocras:
1 urnpr.rU
c
1
w
pacTBopa
coAepXI4T
aKmusHoe
6eu4ecm6o:
rpl4nTopenl'IHa
aIIeTaT
100
MKr'
qro
3KBuBaJIeHTHO
Tpl4rlTopan"tty
ceo
6oAuoro
ocHOBaHI'Ir
9
5',
6
rrlrr
;
(CnoJvtozameJbHbte
6eu4ecm6q:
Harpltfl
xnopr.rA,
KHCJIOTa
yKcycHatr
JleAflHafl,
BoAa
[nfl
unteruuil.
JlerapctneHHas
{oprvra.
Pacrnop
Arq
uHrexquil'
Onucanue
[po3parlnblfi
6ecqserurfi
pacreop'
(DaptraxoreparreBTllrlecKaq
[pyIIrIa.
Analoru
foHaAoTpoIIIIH
-
pI'InII3I4Hf
ropMoHa'
Kor
ATX
L02A
E04.
Krunu'recKl{e
xapaKTepucrqnrr'
Iloxasauun.
-
llpeaynpex-qeHlre
[pexAeBpeMeHHOIO
noBbIIIIeHI4s
ypoBHq
JIIOTeI4HI43I'IpytoilIefo
fopMoHa
(nf)
y
xeHrlr.rH,
KOTOpbM
IIpoBoAtT
KoHrponHpyeMyry
il'{nepcrl'IMyn{III4IO
q[r{HI4KOB
B
paMKax
BcrroMofareJlbHbrx
perpoAyKrllBHblx
rexHoJlorllfi
(BPT)'
IIpomuoonoKa3ilHun.
llpuuenenue
.{ercanerlTl4Jla
rIporI4BoIIoKa3aHo
B cneAylorul4x
cnyqa-sx
:
-
rroBbrrrleuHa-t{
IIyBCTBLITeJIrHOCTr
K
TpII[TOpenIlHy
aUeTaTy
I4JIII
K
nrO6Orrly
BCIIOMOTaTeJIIHOMy
ftilt"t;"J;"Ha{
rryBcrBr'rerrbHocrb
K
roHaAorponr{H-pr.rrrr{3r4Hr
ropMoHy
(fnPf)
vrLr
K:*o6orray
ApyroMy
aHanory
fnPf;
-
ilepl{
oA
6
epelt
euH
o
crkr
r4Int
K
opMneH[q
fpyAb]o'
Cnoco1
nquJvteHeHun
u
dosot'
Jle.reHue
,{ercanervloM
CneAyeT
HaqI,IHaTb
IIoA
KOHTponeM
Bpatla'
I',IMeIoIIeIO
OIIbIT
B JIeqeHIIII
6ecnloAzs
y
xeHrrlr{H.
,{eranenTl4n
IIpeAHa3HarIex
AJI'
IIOAKO)KHOTo
BBeAeH[q
OAIIH
pa3 B
cyrKr4
B
Hr4xHroro
qacrb
6prouHoft
creHKI'I.
llocle
nepnoft
I4HT'eKIII4I4
p*"-Y::-lfl::-
na6ruoAarr
3a
rrarIr4eHTKaMI4
B
TeqeHHe
30
ruranyr
AJI'
BblflBJleHI'Ig
0I'IMIITOMOB
BO3MOXHOII
annepruqecrofi/uceeAo
-
aJlnepruqecxoft
peaKIII{u
Ha
I4H5gKIIHIS'
llpu
srou
seo6xoAl4Mo
ofecnequrb
Haruqr4e
HaAnexalqlrx
ycJloBrrir
u
cpe4crB
Anfl
Bo3MoxHoro
JIeqeHI'Ig
raKI'IX
pearqnft.
.{alHrefiruue
rrHbeKu14v
na||fleHTbl
MoryT
IIpoBoAI{Tb
caMOCTOflTeJIbHO
IIpI4
ycnoBl{I',I
nonyqeHut
coOTBeTcTByIoUux
LIHcTpyKIIufi'
npa'n
o
[pI'I3HaKax
II ctI